ABSTRACT
The severe acute respiratory syndrome coronavirus 2 has been identified as the cause of a pandemic of respiratory illness in Wuhan, China. Coronavirus disease 2019 may cause mild disease with nonspecific signs and symptoms such as fever, cough, myalgia, and fatigue or severe pneumonia with respiratory failure and sepsis. It is not clear whether coronavirus disease 2019 has an effect on the thyroid gland. Evidence support that patients with coronavirus disease 2019 who are followed up in the intensive care unit may develop temporary thyroid dysfunction as non-thyroidal illness syndrome. Until now, 22 cases of subacute thyroiditis and 5 Graves' diseases potentially related to severe acute respiratory syndrome coronavirus 2 infection have been presented in the literature. Herein, we present 2 cases with subacute thyroiditis and Graves'diseases potentially related to severe acute respiratory syndrome coronavirus 2 infection in the context of the review of the literature. Physicians should be aware of the possible relationship between thyroid dysfunction and coronavirus disease 2019.
ABSTRACT
The severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) virus, was identified as the cause of a pandemic of respiratory illness in Wuhan, China one year ago. The Coronavirus disease 2019 (COVID-19), may cause mild disease with nonspecific signs and symptoms such as fever, cough, myalgia, and fatigue, or severe pneumonia with respiratory failure and sepsis. However, endocrinological manifestations are yet to be established, in patients with COVID-19. The effect of COVID-19 on thyroid function is unknown at this time. Evidence support that patients with COVID-19 who are followed up in intensive care units may develop thyroid dysfunction as a non-thyroidal illness syndrome. Until now, twenty-two cases with subacute thyroiditis and five cases with Graves’ Diseases potentially associated with SARS-CoV-2 infection have been reported in literature. Physicians should be aware of possible relationships between thyroid dysfunction and COVID-19. This study aimed to review thyroid dysfunction in patients with COVID-19, and to overview thyroid diseases that are probably related to COVID-19. © 2021 Universidad Compultense Madrid. All right reserved.
ABSTRACT
Purpose: This study aimed to investigate the association between QTc interval and laboratory parameters in COVID-19 patients before and after the treatment. Materials and Methods: Forty-three COVID-19 patients who had baseline and follow-up ECG findings and laboratory reports were evaluated and 40 patients were included in the study. Results: Among 40 patients, 16 were women and 24 were men. The neutrophil-to-lymphocyte ratio (NLR) and corrected QT (QTc) interval were significantly higher in females than males. After the treatment, a significant fall in CRP and ferritin values, and significantly prolonged QTc interval were seen. A significant positive correlation was observed between QTc interval and age, LDH levels, neutrophil and leukocyte count, NLR, magnesium levels, and heart rate of the patients prior to treatment. A positive correlation was observed between increased QTc interval and decreased LDH levels and NLR after treatment. Conclusion: QTc prolongation was associated with increased inflammatory markers, increased NLR and LDH levels before and after treatment in COVID-19 patients. The increase in the QTc interval was correlated with the reduction in LDH levels and NLR with treatment.
ABSTRACT
This study was performed to evaluate whether the use of drugs in the treatment of osteoporosis in women is associated with COVID-19 outcomes. The results showed that the risk of hospitalization, intensive care unit admission, and mortality was not altered in individuals taking anti-osteoporosis drugs, suggesting no safety issues during a COVID-19 infection. INTRODUCTION: Whether patients with COVID-19 receiving anti-osteoporosis drugs have lower risk of worse outcomes has not been reported yet. The aim of this study was to evaluate the association of anti-osteoporosis drug use with COVID-19 outcomes in women. METHODS: Data obtained from a nationwide, multicenter, retrospective cohort of patients diagnosed with COVID-19 from March 11th to May 30th, 2020 was retrieved from the Turkish Ministry of Health Database. Women 50 years or older with confirmed COVID-19 who were receiving anti-osteoporosis drugs were compared with a 1:1 propensity score-matched COVID-19 positive women who were not receiving these drugs. The primary outcomes were hospitalization, ICU (intensive care unit) admission, and mortality. RESULTS: A total of 1997 women on anti-osteoporosis drugs and 1997 control patients were analyzed. In the treatment group, 1787 (89.5%) women were receiving bisphosphonates, 197 (9.9%) denosumab, and 17 (0.9%) teriparatide for the last 12 months. Hospitalization and mortality rates were similar between the treatment and control groups. ICU admission rate was lower in the treatment group (23.0% vs 27.0%, p = 0.013). However, multivariate analysis showed that anti-osteoporosis drug use was not an independent associate of any outcome. Hospitalization, ICU admission, and mortality rates were similar among bisphosphonate, denosumab, or teriparatide users. CONCLUSION: Results of this nationwide study showed that preexisting use of anti-osteoporosis drugs in women did not alter the COVID-19-related risk of hospitalization, ICU admission, and mortality. These results do not suggest discontinuation of these drugs during a COVID-19 infection.